Rocket Lab said it is delaying the launch of its Neutron rocket until next year. Shares slid 8% to $54.64 in after-hours trading Wednesday.

Vanda Pharmaceuticals said its Phase 3 trial of a social-anxiety treatment failed to meet its endpoint. The stock declined 6% to $3.95 after the bell.

Netcapital said it had regained compliance with Nasdaq's minimum bid rule. Shares gained 36% to $2.16.